Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
接受新辅助阿那曲唑、氟维司群或二者联合治疗的雌激素受体丰富/ERBB2阴性绝经后乳腺癌患者的内分泌敏感性疾病发生率：一项3期随机临床试验
期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2023.6038
Ma, Cynthia X; Suman, Vera J; Sanati, Souzan; Vij, Kiran; Anurag, Meenakshi; Leitch, A Marilyn; Unzeitig, Gary W; Hoog, Jeremy; Fernandez-Martinez, Aranzazu; Fan, Cheng; Gibbs, Richard A; Watson, Mark A; Dockter, Travis J; Hahn, Olwen; Guenther, Joseph M; Caudle, Abigail; Crouch, Erika; Tiersten, Amy; Mita, Monica; Razaq, Wajeeha; Hieken, Tina J; Wang, Yang; Rimawi, Mothaffar F; Weiss, Anna; Winer, Eric P; Hunt, Kelly K; Perou, Charles M; Ellis, Matthew J; Partridge, Ann H; Carey, Lisa A
